Why Is Molnupiravir So Hard to Find? [Explained for 2026]

You tested positive for COVID-19, your doctor called in a prescription for Lagevrio (molnupiravir), and you headed to your pharmacy — only to find empty shelves or a confused pharmacist who's never heard of it. Sound familiar? You're not alone.

Molnupiravir is an oral antiviral medication authorized by the FDA under an Emergency Use Authorization (EUA) for the treatment of mild-to-moderate COVID-19. While it's not in active shortage, finding it stocked at any given pharmacy near you can still be a frustrating experience. In this post, we'll break down exactly why that is — and what you can do about it.

What Is Molnupiravir (Lagevrio)?

Molnupiravir, sold under the brand name Lagevrio and made by Merck, is an oral antiviral pill taken as 800 mg (4 capsules) every 12 hours for 5 days. It works by introducing errors into the COVID-19 virus's genetic code, preventing it from replicating. It was authorized by the FDA in December 2021 and is only available to adults 18 and older who are at high risk for serious illness and for whom other COVID treatments like Paxlovid are not accessible or appropriate.

Unlike Paxlovid, molnupiravir has no known drug-drug interactions, making it a valuable option for patients on complex medication regimens. That said, it is currently the third-line treatment preference according to NIH guidelines — behind Paxlovid and remdesivir — which directly affects how pharmacies stock it.

Why Is Molnupiravir Difficult to Find at Pharmacies?

There are several reasons molnupiravir can be hard to locate at your local pharmacy in 2026:

1. It's a Third-Line Treatment

Federal and clinical guidelines rank Paxlovid first, remdesivir second, and molnupiravir third for COVID-19 treatment. This hierarchy affects ordering patterns. Pharmacies stock what's most prescribed, and since the majority of eligible patients receive Paxlovid, molnupiravir may sit lower on pharmacy ordering lists. Smaller pharmacies may not keep it in stock at all if they've had low historical demand.

2. It Never Received Full FDA Approval

Lagevrio is still authorized under an Emergency Use Authorization (EUA), not a standard FDA approval. This affects how prominently it is marketed and how consistently it is stocked across pharmacy chains. No generic version exists, meaning there's only one source: Merck. Price volatility and the lack of direct-to-pharmacist prescribing (unlike Paxlovid) further limit its reach.

3. The Federal Distribution Program Ended

When the COVID-19 public health emergency ended, molnupiravir transitioned from a federally managed, no-cost distribution program to standard commercial pharmacy channels. This transition disrupted supply chains and changed which pharmacies carry it. Retail prices are now over $1,000 for a 5-day course without insurance or savings programs, which may also discourage some pharmacies from keeping it on their shelves.

4. Demand Is Seasonal and Variable

COVID-19 case counts spike during winter months and surge waves, which can temporarily outpace pharmacy ordering. Because molnupiravir has a niche patient population (those who can't take Paxlovid), its demand is harder to predict. Pharmacies may not reorder fast enough during surges.

Is There a Molnupiravir Shortage in 2026?

As of 2026, there is no active, widespread FDA-declared shortage of molnupiravir. Merck continues to manufacture and supply it commercially. However, "no formal shortage" doesn't mean it's easy to find. Localized availability varies significantly by region, pharmacy chain, and time of year. In rural areas or during COVID surges, you may visit multiple pharmacies before finding one with it in stock.

Who Typically Gets Prescribed Molnupiravir?

Molnupiravir is typically prescribed to adults who:

Have mild-to-moderate COVID-19 with a positive test result

Are at high risk for severe disease (age 50+, obesity, diabetes, heart or lung disease, immunocompromised)

Cannot take Paxlovid due to drug interactions with their current medications

Cannot receive IV remdesivir (Veklury) due to access or logistical barriers

Are within 5 days of symptom onset

What Can You Do If You Can't Find Molnupiravir?

If you're struggling to find molnupiravir in stock near you, here are your options:

Call multiple pharmacies — chain pharmacies (CVS, Walgreens, Rite Aid) and independent pharmacies may have different stock levels.

Ask your pharmacist to order it — if it's not on their shelf, most pharmacies can order it within 24-48 hours if you have a valid prescription.

Use a service like medfinder — medfinder calls pharmacies near you to check which ones have your medication in stock, saving you time and stress.

Talk to your doctor about alternatives — if molnupiravir can't be found in time, your provider may reassess whether Paxlovid (with managed drug interactions) or another option is feasible.

How medfinder Can Help

Time is critical with molnupiravir — you need to start within 5 days of symptoms. That doesn't leave much time to call a dozen pharmacies. medfinder is a paid service that calls pharmacies near you to find which ones have your medication ready to fill. You provide your medication, dose, and zip code — we do the calling. Results are texted directly to you, so you can go straight to the pharmacy that has it in stock.

For more context on molnupiravir's supply situation, check out our Molnupiravir Shortage Update for 2026.

Bottom Line

Molnupiravir isn't formally in shortage, but it's not as widely stocked as Paxlovid, and its availability can vary significantly depending on where you live and when you need it. The combination of its third-line guideline status, brand-only supply, end of federal distribution, and variable demand all contribute to the challenge. Don't waste precious days calling pharmacies one by one — there are smarter ways to find what you need.